Why I'm Considering Selling Pfizer for Tax-Loss Harvesting Purposes
As the year comes to an end, it's time to think about which stocks to sell for tax-loss harvesting. One stock I'm considering letting go is pharma giant (NYSE: PFE). The company's shares have dropped by a whopping 43.5% in 2023, making it a prime candidate for tax-loss harvesting.
And while Pfizer is still a dividend-paying powerhouse and its shares screen as "cheap" based on multiple valuation metrics, I'm losing faith in the company's ability to right the ship, so to speak. Here are two other issues driving me toward hitting the "sell" button on this pharma stock.
Image source: Getty Images.
Source Fool.com
Pfizer Inc. Aktie
25,77 €
0,14 %
Die Pfizer Inc. Aktie steht gut da: Deutlich mehr Buy- als Sell-Einschätzungen in der Community.
Das Kursziel von 41 € für Pfizer Inc. impliziert eine deutliche Steigerung um über 50% gegenüber 25.77 €.
